Heart Failure with reduced ejection fraction
The clinical research activity is centered on heart failure with reduced ejection fraction, with attention to patients who develop secondary pulmonary hypertension and related changes in cardiopulmonary function.
- Heart failure
- Reduced ejection fraction
- Pulmonary hypertension
- Right heart catheterization
Interest extends to hemodynamic changes in the pulmonary circulation, including pulmonary artery pressure and pulmonary vascular resistance in the setting of advanced cardiac dysfunction.
Cardiovascular Pharmacotherapy
The sponsor’s therapeutic focus includes medical management of heart failure using angiotensin-converting enzyme inhibitors and angiotensin receptor-neprilysin inhibition, with clinical interest in comparative cardiovascular treatment effects.
- Sacubitril/valsartan
- Enalapril
- ACE inhibitor therapy
- Neprilysin inhibition
Research activity is directed toward treatment-related changes in cardiopulmonary pressure load and vascular resistance in patients with HFrEF.
Pulmonary Vascular Disease
Clinical interest also covers the interaction between left-sided cardiac failure and pulmonary vascular remodeling, particularly when elevated pressures affect the right side of the heart and the lung circulation.
- Pulmonary artery pressure
- Pulmonary vascular resistance
- Cardiopulmonary hemodynamics
- Secondary pulmonary hypertension
This area reflects a focus on physiologic consequences of heart failure within the pulmonary circulation and the right heart.
